ClinicalTrials.Veeva

Menu
F

Fred Hutchinson Cancer Research Center | Seattle, WA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

cyclophosphamide
Paclitaxel
Carboplatin
Cyclophosphamide
vincristine sulfate
Fludarabine
methotrexate
etoposide
cyclosporine
Bevacizumab

Parent organization

This site is a part of Fred Hutchinson Cancer Research Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

62 of 739 total trials

9-ING-41 in Patients with Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and e...

Active, not recruiting
Neoplasm of Lung
Neoplasms Pancreatic
Drug: Gemcitabine - 21 day cycle
Drug: 9-ING-41

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Drug: BGB-16673

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-...

Not yet enrolling
Advanced Solid Tumor
Drug: BG-C137

A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-...

Active, not recruiting
Hiv
Biological: Core-g28v2 60mer mRNA Vaccine
Biological: eOD-GT8 60mer mRNA Vaccine

This is a Phase 1/2, Open-label, Dose Escalation study to investigate axatilimab in participants with active chronic graft versus host disease (cGVHD...

Active, not recruiting
Chronic Graft-versus-host-disease
Drug: axatilimab

This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...

Active, not recruiting
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma
Biological: axicabtagene ciloleucel
Drug: Cyclophosphamide

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Enrolling
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Drug: Physician's Choice medications
Drug: Pacritinib

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Lymphoma, Non Hodgkin
Drug: BTCT4465A (Mosunetuzumab) IV
Drug: BTCT4465A (Mosunetuzumab) SC

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essen...

Active, not recruiting
Essential Thrombocythemia
Drug: Ropeginterferon alfa-2b-njft (P1101)
Locations recently updated

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Venetoclax

This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig alone or in combination with tiragolumab compared with atezolizuma...

Active, not recruiting
Urothelial Cancer
Drug: Tiragolumab
Drug: Atezolizumab

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or...

Active, not recruiting
Chronic Graft-versus-host-disease
Drug: Axatilimab

BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability...

Active, not recruiting
Colorectal Carcinoma
KRAS G12V
Drug: BDTX-4933

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with tem...

Enrolling
Astrocytoma, Grade III
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Drug: Debio 0123
Drug: Temozolomide

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelod...

Active, not recruiting
Higher Risk Myelodysplastic Syndromes
Drug: evorpacept
Drug: azacitidine

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGV...

Enrolling
aGVHD
Graft Versus Host Disease
Drug: EQ001 Placebo
Biological: Itolizumab

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorour...

Enrolling
Adenocarcinoma, Pancreatic Ductal
Drug: mFOLFIRINOX
Drug: Autogene cevumeran

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intravenous (IV) or subcutaneous (SC) mosunetu...

Active, not recruiting
B-cell Non-Hodgkin Lymphoma
Drug: Polatuzumab vedotin
Drug: Tocilizumab

Trial sponsors

Fred Hutchinson Cancer Center (FHCC) logo
SWOG Cancer Research Network logo
National Cancer Institute (NCI) logo
C
G
Medical College of Wisconsin logo
Celgene logo
Alliance for Clinical Trials in Oncology logo
C
ECOG-ACRIN Cancer Research Group logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems